Clinical Trials Browser

NCT00569127 2026-05-26

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Phase 3 Active not recruiting

427 enrolled 17 charts

EndocrineNET

Neuroendocrine Tumors

NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Phase 3 Recruiting

220 enrolled

EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

NCT06881992 2026-05-18

Tumor HI

Phase 3 Recruiting

16 enrolled

EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Clinical Trials

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Tumor HI

ADJUPANET

LEVEL

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NETTER-3

CAREFNDR

COMPETE

ACTION-1

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

18F-DOPA II - PET Imaging Optimization

NETTER-2

SORENTO

PReCedeNT

COMPOSE

START-NET

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

RIALTO

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors